FDA
-
-
-
-
-
-
-
INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStromâ„¢ Platform
-
-
-
-
-
-
-
INmune Bio files CORDStrom patent in U.S. after favorable PCT opinion
-
-
-
-
-
-
-
INmune Bio reports positive MRI results in Alzheimer's trial
-
-
-
-
-
-
-
INmune Bio receives FDA fast track designation for alzheimer's drug
-
-
-
-
-
-
-
INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th
-
-
-
-
-
-
-
INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.
-
-
-
-
-
-
-
INmune Bio submits CORDStrom pre-application to UK regulators for RDEB
-
327,953 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

